SBI Securities
TRDA icon

SBI Securities’s Entrada Therapeutics TRDA Stock Holding History

SBI Securities’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13 Hold
2
– – ﹤0.01% 3980
2026
Q2 		$15 Buy
+2
New +$19 ﹤0.01% 3892
2025
Q2 		– Sell
-1
Closed -$9 – 4232
2025
Q1 		$9 Buy
+1
New +$12 ﹤0.01% 3980

Other funds holding TRDA

Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

SBI Securities's TRDA Position: Q3 2026 in Review

SBI Securities held its Entrada Therapeutics (TRDA) position steady in Q3 2026 at 2 shares worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #3980.

SBI Securities first reported a position in TRDA in Q1 2025 and has held it in 3 quarters since. The position peaked at $15 in Q2 2026. 15 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • SBI Securities held 2 shares of Entrada Therapeutics worth $13 as of Q3 2026.
  • SBI Securities left its Entrada Therapeutics share count unchanged in Q3 2026.
  • Entrada Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3980 holding.
  • SBI Securities first reported a position in Entrada Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • SBI Securities's Entrada Therapeutics position peaked at $15 in Q2 2026.
  • 15 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.